A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia

Purpose: Efficient strategies to screen promising agents in early phase development are essential for rapid progress in breast cancer chemoprevention. We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2004-11, Vol.10 (22), p.7583-7591
Hauptverfasser:	STEARNS, Vered, COOP, Andrew, SINGH, Baljit, GALLAGHER, Ann, YAMAUCHI, Hideko, LIEBERMAN, Ronald, PENNANEN, Marie, TROCK, Bruce, HAYES, Daniel F, ELLIS, Matthew J
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Apoptosis Biological and medical sciences Biomarkers Biomarkers, Tumor Biopsy Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Carcinoma in Situ Carcinoma, Intraductal, Noninfiltrating - drug therapy Cell Proliferation Cohort Studies Female Humans Immunohistochemistry Medical sciences Middle Aged Monoterpenes - therapeutic use Pharmacology. Drug treatments Pilot Projects Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose: Efficient strategies to screen promising agents in early phase development are essential for rapid progress in breast cancer chemoprevention. We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the “window” between diagnostic and definitive surgery. Experimental Design: Eligible patients included those with a diagnosis of atypical ductal hyperplasia, ductal carcinoma in situ , lobular carcinoma in situ , or invasive carcinoma (
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-04-0295